Inflammation–Metabolite in Multiple Sclerosis: The Emerging Role of Interleukin-7
Multiple sclerosis (MS) is a complex inflammatory and neurodegenerative disease in which immune dysregulation, demyelination, and neuronal injury interact through highly complex biological pathways. The study by Yan and colleagues approaches this complexity by examining whether circulating inflammatory proteins can influence MS risk through changes in metabolism. Rather than treating inflammation and metabolic dysfunction as independent features of disease, the investigators tested the possibility of an interconnected inflammatory–metabolic network. Their analysis included 91 inflammatory plasma proteins and an extensive set of potential metabolic mediators comprising 1,091 blood metabolites, 309 metabolite ratios, 233 circulating metabolic traits, 338 cerebrospinal fluid (CSF) metabolites, and measures related to iron metabolism. The primary objective was therefore not merely to identify molecules associated with MS, but to determine whether genetically predicted inflammatory activity could causally modify metabolic pathways that subsequently alter susceptibility to the disease. This approach is particularly relevant because previous research has implicated cytokines, altered lipid metabolism, iron dysregulation, sphingolipids, and changes in CSF metabolites in MS, while the direction and causal relationships among these factors have remained difficult to establish.
Mendelian Randomization as a Framework for Causal Investigation
A major strength of the investigation is its use of bidirectional two-sample and two-step Mendelian randomization (MR). Mendelian randomization employs genetic variants associated with an exposure as instrumental variables to investigate whether the exposure has a potentially causal effect on an outcome. Because genetic variants are established before disease development, this strategy can reduce some of the problems of reverse causation and confounding that affect conventional observational studies. The investigators organized their analysis into three principal stages: first, testing the effects of 91 inflammatory proteins on MS; second, identifying metabolic traits associated with MS; and third, evaluating whether selected metabolites mediated inflammatory protein–MS relationships. The MS outcome was evaluated independently in the International Multiple Sclerosis Genetics Consortium dataset, consisting of 14,802 cases and 26,703 controls, and in the UK Biobank, containing 1,356 cases and 395,209 controls. The investigators also applied stringent procedures for genetic instrument selection and performed several sensitivity analyses, including MR-Egger regression, MR-PRESSO, Cochran's Q, leave-one-out analysis, and Bayesian Weighted Mendelian Randomization. These complementary approaches were intended to assess heterogeneity, pleiotropy, weak-instrument effects, and the influence of individual genetic variants.
Interleukin-7 Emerges as the Principal Inflammatory Candidate
Among the inflammatory proteins evaluated, interleukin-7 (IL-7) emerged as the most consistent candidate connecting immune signaling to MS risk. In the IMSGC dataset, genetically predicted higher IL-7 was associated with an estimated 40% increase in MS odds using the primary inverse-variance weighted method, with an odds ratio of 1.40 and a 95% confidence interval of 1.07–1.83. In the UK Biobank, the effect was substantially smaller, with an odds ratio of 1.001 per unit of the genetically predicted exposure, but it remained nominally statistically significant. Importantly, several complementary MR methods supported the association, although not every sensitivity estimator reached significance in both cohorts. The analysis also found no convincing evidence that genetic liability to MS caused increased IL-7 levels, strengthening the authors' interpretation of a predominantly one-directional relationship from IL-7 toward MS rather than the reverse. Biologically, this observation is plausible within the framework discussed by the authors because IL-7 is closely involved in T-cell survival and expansion, and previous genetic studies have implicated the IL-7 receptor pathway in MS susceptibility. The investigators therefore interpret IL-7 not simply as an inflammatory correlate of disease, but as a potential upstream contributor to autoimmune processes relevant to MS development.
Six Metabolic Traits Form a Potential Bridge Between IL-7 and MS
The most distinctive contribution of the study is its attempt to identify metabolic intermediates through which IL-7 might influence MS. Six circulating metabolic traits fulfilled the authors' mediation criteria: taurocholenate sulfate, anthranilate, taurodeoxycholate, the leucine-to-phosphate ratio, albumin, and a specific sphingomyelin species designated sphingomyelin (d18:1/24:1, d18:2/24:0). The reported mediated proportions ranged from approximately 3.9% for albumin to 16.5% for taurodeoxycholate, while taurocholenate sulfate, anthranilate, the leucine-to-phosphate ratio, and sphingomyelin accounted for intermediate proportions of the estimated IL-7 effect. However, the precision of these estimates is important. Table 3 shows that confidence intervals for most mediation effects included zero, whereas anthranilate demonstrated a comparatively more precise positive mediation estimate of β = 0.028 with a 95% confidence interval of 0.01–0.06. Thus, the findings should be interpreted as evidence prioritizing candidate pathways rather than as definitive proof that each metabolite mediates IL-7-related MS risk. The results nevertheless provide a mechanistic framework in which inflammatory signaling may influence disease susceptibility partly through alterations in peripheral metabolism.
Bile Acids, the Kynurenine Pathway, and Sphingolipid Biology
Several of the identified metabolites converge on biologically relevant pathways. Taurocholenate sulfate and taurodeoxycholate are related to bile acid metabolism, which has important functions beyond digestion, including lipid regulation and immunomodulation. The authors propose that disturbances in bile acid metabolism could participate in MS through effects on immune signaling, lipid peroxidation, and neurodegenerative processes. Anthranilate represents another particularly interesting candidate because it belongs to the tryptophan–kynurenine pathway, a metabolic system widely connected with immune regulation and neuroinflammation. In the study, anthranilate was the metabolite with the most clearly positive mediation estimate, leading the authors to suggest that cytokine signaling and tryptophan metabolism may interact in shaping MS susceptibility. Sphingomyelin adds a further layer of biological relevance because sphingolipids are structural components of myelin and participate in neuronal and immune-cell signaling. Interestingly, the genetically predicted association for the specific sphingomyelin species identified in this study was positive, whereas some observational studies have reported lower sphingomyelin levels in people with MS. The authors suggest that different molecular species, compensatory metabolic responses, or differences between cross-sectional measurements and genetically estimated lifelong exposures may help explain this apparent discrepancy.
Negative Findings for Iron and Cerebrospinal Fluid Metabolism Are Equally Informative
The study also provides important negative findings. Iron dysregulation has long been implicated in MS, particularly because iron accumulation can occur in inflammatory lesions and iron-containing immune cells are observed in chronically active disease. Although the authors found evidence suggesting that iron metabolism itself may be associated with MS risk in the IMSGC dataset, they did not identify significant interactions linking inflammatory proteins to iron metabolism in the proposed mediation pathway. Another notable observation was the absence of identified mediation through CSF metabolites. The mediating signals associated with IL-7 were found in circulating serum or blood metabolic traits rather than in the analyzed CSF metabolome. This led the authors to emphasize the possibility that IL-7 may influence MS partly through peripheral metabolic intermediates rather than through detectable changes in the measured central nervous system metabolites. These findings should not be interpreted as demonstrating that iron or CSF metabolism is irrelevant to MS. Instead, they indicate that, within the available genetic datasets and analytical framework, the investigators could not establish those factors as mediators of the IL-7–MS relationship.
Clinical Significance, Limitations, and Future Directions
The findings raise several potentially important translational hypotheses. If IL-7 contributes causally to MS and partly operates through bile acid, kynurenine, or sphingolipid metabolism, then IL-7 signaling and associated metabolic signatures could eventually become targets for therapeutic development, biomarker research, or genetic–metabolic risk stratification. The authors specifically discuss the possibility of modulating IL-7 signaling and evaluating IL-7-associated metabolites as diagnostic or prognostic biomarkers, while emphasizing that such applications would require substantial clinical validation. Several limitations make such caution essential. Residual pleiotropy cannot be completely excluded; the genetic association threshold used for instrument selection was less stringent than the conventional genome-wide significance threshold; several effect sizes were modest; many mediation estimates had wide confidence intervals; unidentified mediators may account for additional portions of the inflammatory–metabolic relationship; and the study was based predominantly on populations of European ancestry, limiting generalizability to other groups. Consequently, the principal value of this study is not that it establishes an immediate new treatment for MS, but that it identifies IL-7 as a genetically supported inflammatory candidate and places several metabolic pathways downstream of it for further experimental and clinical investigation. The work therefore advances a more integrated model of MS in which immune signaling and systemic metabolism may jointly contribute to disease susceptibility and provides a foundation for future studies seeking to validate these mechanisms in diverse populations and biological systems.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Yan, W., Jianhong, W., Ping, G., & Linming, Z. (2025). Inflammation-metabolite crosstalk in multiple sclerosis: A mediation Mendelian randomization study of plasma inflammatory proteins, iron, and serum/cerebrospinal fluid metabolites. Science Progress, 108(3), 00368504251378619.
